While the coronavirus has impacted millions of Americans across the United States, it has hit the elderly population particularly hard. In fact, more than 40 percent of coronavirus deaths in the U.S. have been linked to long-term care facilities, according to a New York Times survey. In an effort to bring those numbers down, pharmaceutical company Eli Lilly, in partnership with the National Institutes of Health (NIH), has just launched a late-stage antibody treatment trial focusing on residents and staff at nursing homes.
"COVID-19 has had a devastating impact on nursing home residents," Lilly's chief scientific officer Daniel Skovronsky said in a statement. "We're working as fast as we can to create medicines that might stop the spread of the virus to these vulnerable individuals."
The trial is expected to enroll up to 2,400 participants who live or work at a facility and have recently been diagnosed with the disease. The trial will evaluate the safety and success of using LY-CoV555, a potent, neutralizing antibody that works against the spike protein of the novel coronavirus. The trial will look at whether a single dose of the antibody treatment reduces the rate of infection over four weeks as well as symptoms over eight weeks.
"The importance of these kinds of therapies for people like the elderly or immunocompromised is that they can provide the hope and the safety net that these people really need right now," said Andrew Adams, vice president of new therapeutic modalities & COVID-19 research at Eli Lilly, who is overseeing the trial. "I think people in those populations are really desperate and looking for something to help with the coronavirus."
Eli Lilly is taking its trial on the road with customized mobile research units that can travel directly to areas that are experiencing outbreaks.
"This is an interesting solution, to bring the medicine to these vulnerable patients," said Adams. "This lets us be flexible and move these trials around the country, tracking these trials as we come across them."
Adams said he is hoping Eli Lilly will have results on the efficacy of these antibodies in the fourth quarter of this year. Even if successful, though, he says research for a vaccine needs to continue.
"These have to be thought of as more of a bridge, where a vaccine provides long-term protection in terms of years of immunity, where we will provide hopefully in the range of months with these types of treatments. We hope this to be a short-term bridge to the long-term effective vaccination," he said.
Heila Technologies, a startup that develops hardware and software to integrate renewables and batteries on a microgrid, is helping to power the first clean energy microgrid for Auto Mercado, a top supermarket chain in Costa Rica. The plant will reduce 20 tons of CO2 emissions per year. Heila Technologies CEO Francisco Morocz joins Cheddar Climate to discuss.
The U.S. has a million-ton problem: each year, hundreds of pounds of plastic waste are produced per person, and that leads to close to 2 million tons of that waste leaking into the environment. Eight million tons end up in the ocean, where it hinders marine life, damages ecosystems, and impacts industry. But in recent years, Congress has introduced measures including the Save our Seas act to try to mitigate the issue and turn our plastic problem around. Sen. Chris Murphy (D-CT) joins Cheddar Climate to discuss why the U.S. is the top global polluter of plastic, what Congress is doing to try to fix the issue, and more.
Daniel Huppmann, researcher at International Institute for Applied Systems Analysis, joins Cheddar Climate, where he explains how the global economy could be 2% bigger by 2100 if the world can hold global warming below 1.5°C.
While the World Health Organization strongly advises against a COVID-19 vaccine mandate, national and local governments are moving to make inoculations compulsory. Cheddar News speaks with Dr. Joel Zinberg of the Competitive Enterprise Institute on the issue.
Cheddar breaks down the challenges of plastic recycling and what one company is doing to help offset the negative environmental impact of single-use plastics.
Earlier this year, JetBlue flew its inaugural flight into the United Kingdom. It was a game changer — not only did the airline enter the transatlantic market, but the plane that completed the flight was a single-aisle jet. For decades, flying the distance was synonymous with jumbo jets, but today narrow-body aircraft are now proving they are up for the task — and maybe even the best option. In this episode, Cheddar examines why airlines are betting on narrow-body aircraft.
Carlo and Baker discuss the sweeping new vaccine mandate in NYC that will target all private businesses. Plus, Trump's media venture gets its CEO and more.
Humans are scientifically the most successful species in the history of planet earth. And for this we can thank our opposable thumbs, proportionally large brains, and our upright posture. But for all our anatomical wonders, we still have some pretty major flaws.
